Everything below concerns mass spectrometry. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-14. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
| Property | Value | Notes |
|---|---|---|
| Appearance as powder | White to off-white solid | Minor batch-to-batch variation is normal |
| Solubility class | Soluble in water and aqueous buffers | Dissolution can be slowed by aggregates |
| Typical storage temperature | Minus 20 degrees Celsius or below | Protected from light and moisture |
| Storage after reconstitution | 2 to 8 degrees Celsius, short term | Longer holding requires freezing |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity and identity confirmation |
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
The attenuator allows more time for the attenuator sequence domains to form loop structures, but does not produce a protein that is used in later tryptophan synthesis. Attenuation is a second mechanism of negative feedback in the trp operon. While the TrpR repressor decreases transcription by a factor of 70, attenuation can further decrease it by a factor of 10, thus allowing accumulated repression of about 700-fold. Attenuation is made possible by the fact that in prokaryotes (which have no nucleus), the ribosomes begin translating the mRNA while RNA polymerase is still transcribing the DNA sequence. This allows the process of translation to directly affect transcription of the operon. At the beginning of the transcribed genes of the trp operon is a sequence of 140 nucleotides termed the leader transcript (trpL). This transcript includes four short sequences designated 1–4. Sequence 1 is partially complementary to sequence 2, which is partially complementary to sequence 3, which is partially complementary to sequence 4. Thus, three distinct secondary structures (hairpins) can form: 1–2, 2–3 or 3–4. The hybridization of strands 1 and 2 to form the 1–2 structure prevents the formation of the 2–3 structure, while the formation of 2-3 prevents the formation of 3–4. The 3–4 structure is a transcription termination sequence, once it forms RNA polymerase will disassociate from the DNA and transcription of the structural genes of the operon will not occur. Part of the leader transcript codes for a short polypeptide of 14 amino acids, termed the leader peptide.
Doses of naltrexone of 25 to 150 mg/day have been found to produce significant increases in levels of β-endorphin, cortisol, and LH, equivocal changes in levels of prolactin and testosterone, and no significant changes in levels of adrenocorticotrophic hormone (ACTH) or follicle-stimulating hormone (FSH). Naltrexone influences the hypothalamic–pituitary–adrenal axis (HPA axis) probably through interference with opioid receptor signaling by endorphins. Blockade of MORs is thought to be the mechanism of action of naltrexone in the management of opioid dependence—it reversibly blocks or attenuates the effects of opioids. It is also thought to be involved in the effectiveness of naltrexone in alcohol dependence by reducing the euphoric effects of alcohol. The role of KOR modulation by naltrexone in its effectiveness for alcohol dependence is unclear but this action may also be involved based on theory and animal studies.
Lisdexamphetamine was developed by Robert Oberlender at New River Pharmaceuticals, under the name NRP104, before being bought by Takeda Pharmaceuticals through its acquisition of Shire Pharmaceuticals, prior to market release. It was developed to create a longer-lasting and less-easily abused version of dextroamphetamine, as the requirement of conversion into dextroamphetamine via enzymes in the red blood cells delays its onset of action, regardless of the route of administration. In February 2007, the US Food and Drug Administration (FDA) approved lisdexamphetamine for the treatment of ADHD. In August 2009, Health Canada approved the marketing of lisdexamphetamine for prescription use. In January 2015, lisdexamphetamine was approved by the FDA for the treatment of binge eating disorder in adults. The FDA gave tentative approval to generic formulations of lisdexamphetamine in 2015. The expiration date for patent protection of lisdexamphetamine in the US was 24 February 2023. The Canadian patent expired 20 years from the filing date of 1 June 2004. Production quotas for 2016 in the United States were 29,750 kg.
==== Tricyclics ==== Asenapine (Saphris) – Of the dibenzo-oxepino pyrrole class of atypical antipsychotics. Used for the treatment of schizophrenia and acute mania associated with bipolar disorder. Clozapine (Clozaril) – Of the dibenzodiazepine class of atypical antipsychotics. Requires routine laboratory monitoring of complete blood counts every one to four weeks due to the risk of agranulocytosis. It has unparalleled efficacy in the treatment of treatment-resistant schizophrenia. Loxapine (Adasuve, Loxitane, Loxapac)- Of the Dibenzoxazepines class of atypical antipsychotic. Uniquely among all antipsychotics, Loxapine's major metabolite is Amoxapine, a Tricyclic (sometimes classified as Tetracyclic ) antidepressant on its own right. Loxapine is said to have antidepressives properties through Amoxapine, which acts, like other Tricyclic antidepressant, as a Serotonin–norepinephrine reuptake inhibitor.
Sources: en.wikipedia.org
The Altıkulaç Sarcophagus, or Çan sarcophagus, is an early 4th century BCE (400–375 BCE) sarcophagus. It is sometimes said to be in the Greco-Persian style. The sarcophagus was found in 1998 in a circular corbel-vaulted tomb within the Çingenetepe tumulus, in the village of Altıkulaç, near Çan, in the eastern Troad, about halfway between Troy and Daskyleion, in what was anciently Hellespontine Phrygia. It was looted and damaged in the process, but a large part of the reliefs remained intact. It is made of painted marble carved in low relief, and dated to the 1st quarter 4th century BCE. It was made at about the same time as the famous tombs in Lycia. The sarcophagus can probably be attributed to an Anatolian dynast of Hellespontine Phrygia. The longer face of the sarcophagus is decorated with two hunting scenes, the hunting of a fallow buck on the left portion, and the hunting of a boar on the right portion. The shorter face of the sarcophagus is decorated with a battle scene, with a mounted, armoured warrior, accompanied by his henchman, spearing a fallen light-armed soldier, probably a Greek psilos. The rider was almost certainly the dynast to whom the sarcophagus belonged. His henchman, judging from his appearance, was probably a Greek mercenary in the service of the cavalryman, a common occurrence at the time. The other two sides are undecorated. The sarcophagus nevertheless derives from a long tradition of royal iconography in the Near East, especially visible in the tombs of Asia Minor.
== Further reading == Liu, Shuchang; Liu, Feng; Jia, Haihong; Yan, Yan; Wang, Hongfang; Guo, Xingqi; Xu, Baohua (2016). "A glutathione S-transferase gene associated with antioxidant properties isolated from Apis cerana cerana". The Science of Nature. 103 (5–6): 43. Bibcode:2016SciNa.103...43L. doi:10.1007/s00114-016-1362-3. PMID 27126403. S2CID 17260700. Hinchman, Cheri A.; Ballatori, Nazzareno (1994). "Glutathione conjugation and conversion to mercapturic acids can occur as an intrahepatic process". Journal of Toxicology and Environmental Health. 41 (4): 387–409. Bibcode:1994JTEHA..41..387H. doi:10.1080/15287399409531852. PMID 8145281.
In this system, the antibody conjugate would hypothetically be delivered first such that it binds to the target location, followed by the administration of the drug conjugate, whose chain 1 would dimerize with the antibody chain 2, resulting in targeted drug delivery. Since then, hundreds of investigations have been reported in the literature discussing novel drug delivery systems consisting of various coiled coil supramolecular assemblies, such as fibers, hydrogels, and nanostructures.
== Background == The monoisotopic mass is not used frequently in fields outside of mass spectrometry because other fields cannot distinguish molecules of different isotopic composition. For this reason, mostly the average molecular mass or even more commonly the molar mass is used. For most purposes such as weighing out bulk chemicals only the molar mass is relevant since what one is weighing is a statistical distribution of varying isotopic compositions. This concept is most helpful in mass spectrometry because individual molecules (or atoms, as in ICP-MS) are measured, and not their statistical average as a whole. Since mass spectrometry is often used for quantifying trace-level compounds, maximizing the sensitivity of the analysis is usually desired. By choosing to look for the most abundant isotopic version of a molecule, the analysis is likely to be most sensitive, which enables even smaller amounts of the target compounds to be quantified. Therefore, the concept is very useful to analysts looking for trace-level residues of organic molecules, such as pesticide residue in foods and agricultural products. Isotopic masses can play an important role in physics, but physics less often deals with molecules. Molecules differing by an isotope are sometimes distinguished from one another in molecular spectroscopy or related fields; however, it is usually a single isotope change on a larger molecule that can be observed rather than the isotopic composition of an entire molecule.
== See also == CHAIN (disambiguation) The Chain (disambiguation) Chain of Ponds (disambiguation) Chain of thought (disambiguation) Chained (disambiguation) Chane (disambiguation) Daisy chain (disambiguation) Serial (disambiguation)
Sources: en.wikipedia.org
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.
Hydrolysis, oxidation of susceptible residues, and aggregation all contribute, and their rates depend on pH, temperature, and concentration. Dissolved oxygen and trace metal ions accelerate oxidation. Keeping solutions cold, dilute, and free of unnecessary handling reduces these pathways.
Not always, because the value depends on the detection wavelength, the gradient, and how peak areas are integrated. A figure of ninety-eight percent from one laboratory may not mean the same as the same number from another. Comparing full chromatograms and mass spectra is more informative than comparing a single number.
The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.